U.S. markets close in 5 hours 14 minutes

Novo Nordisk A/S (0QIU.IL)

IOB - IOB Precio retrasado. Moneda en DKK.
Añadir a la lista de seguimiento
986.50+8.45 (+0.86%)
A partir del 03:14PM BST. Mercado abierto.

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 59,337

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Lars Fruergaard JorgensenPres, CEO & Member of Management Board32.3MN/D1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board12.8MN/D1971
Mr. Henrik Ehlers WulffExec. VP of Product Supply, Quality & IT and Member of the Management Board12.9MN/D1970
Ms. Camilla SylvestExec. VP of Commercial Strategy & Corp. Affairs and Member of the Management Board12.6MN/D1972
Dr. Martin Holst LangeExec. VP of Devel. & Member of the Management Board12.2MN/D1970
Dr. Marcus Schindler Ph.D.EVP of Research & Early Devel., Chief Scientific Officer & Member of the Management Board12.2MN/D1966
Mr. Maziar Mike DoustdarExec. VP of International Operations & Member of the Management BoardN/DN/D1970
Mr. Douglas J. LangaExec. VP of North America Operations & Member of Management BoardN/DN/D1966
Mr. Ludovic HelfgottExec. VP, Head of Rare Disease & Member of Management BoardN/DN/D1974
Ms. Tania SabroeExec. VP of Global People & Organisation and Member of Management BoardN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en DKK.

Descripción

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Gestión corporativa

La calificación ISS Governance QuickScore de Novo Nordisk A/S a partir del 1 de octubre de 2023 es 2. Las puntuaciones principales son Auditoría: 2; Junta: 3; Derechos del accionista: 10; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.